SKYTROFA: payments to doctors
Payments that named SKYTROFA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.5M
- Providers
- 1,281
- Transactions
- 6,587
- Average per transaction
- $230
The per-transaction average — $230 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,281 providers the average total is $1,182, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Ascendis Pharma Inc | $882,708 | 58.3% |
| Ascendis Pharma, Inc. | $399,958 | 26.4% |
| Ascendis Pharma Endocrinology Inc | $231,686 | 15.3% |